Sugi Predict

Sugi Predict / Targets / MAPK10

MAPK10

Mitogen-activated protein kinase 10 · P53779 · MAPK10 on Sugi Atlas →

184,558 patent compounds predicted against MAPK10, 111,072 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Vs-4718 Vs-4718 (SCHEMBL47360) 1.00 12/20
SCHEMBL157014 SCHEMBL157014 1.00 12/20
SCHEMBL186278 SCHEMBL186278 1.00 12/20
Gw620972X Gw620972X (SCHEMBL157875) 1.00 11/20
SCHEMBL47302 SCHEMBL47302 0.84 11/20
SCHEMBL183210 SCHEMBL183210 0.51 9/20
SCHEMBL184151 SCHEMBL184151 0.49 9/20
SCHEMBL183919 SCHEMBL183919 0.65 8/20
SCHEMBL163051 SCHEMBL163051 0.55 7/20
SCHEMBL20495 SCHEMBL20495 0.54 7/20
SCHEMBL183339 SCHEMBL183339 0.51 7/20
SCHEMBL117545 SCHEMBL117545 0.46 7/20
SCHEMBL183898 SCHEMBL183898 0.70 6/20
SCHEMBL183113 SCHEMBL183113 0.63 6/20
SCHEMBL182900 SCHEMBL182900 0.51 6/20
SCHEMBL183227 SCHEMBL183227 0.51 6/20
SCHEMBL183742 SCHEMBL183742 0.36 6/20
SCHEMBL184467 SCHEMBL184467 0.52 5/20
SCHEMBL182609 SCHEMBL182609 0.49 5/20
SCHEMBL183362 SCHEMBL183362 0.46 5/20

Clinical trials — most relevant to MAPK10 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Mechanism of Sorafenib Resistance in Patients With Advanced Hepatocellular Carcinoma PHASE4UNKNOWN
Anti-oxidative Influence From Pomegranate Tablets on Male Sperm Quality in Couples Undergo Infertility Treatments Due to Male Infertility. PHASE3UNKNOWN
A First-in-man Phase I/II Study of Oral ONC201 in Patients With Advanced Cancer PHASE1/PHASE2WITHDRAWN
Bevacizumab and Erlotinib in Treating Patients With Advanced Liver Cancer PHASE2COMPLETED
Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E BRAF Mutations PHASE2ACTIVE_NOT_RECRUITING
HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma PHASE1/PHASE2COMPLETED
Dabrafenib + Trametinib + PDR001 In Colorectal Cancer PHASE2UNKNOWN
To Evaluate the Efficacy Beyond Progression of Vemurafenib+Cobimetinib Associated With Local Treatment Compared to Second-line Treatment in Patients With BRAFV600+ Metastatic Melanoma in Focal Progression With First-line+Vemurafenib+Cobimetinib. PHASE2UNKNOWN
Perifosine in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma PHASE2COMPLETED
A Study of ERAS-007 as Monotherapy or in Combination With ERAS-601 in Patients With Advanced or Metastatic Solid Tumors PHASE1/PHASE2ACTIVE_NOT_RECRUITING
A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations PHASE2RECRUITING
ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic Syndrome PHASE1/PHASE2RECRUITING
Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma PHASE2UNKNOWN
A Study to Evaluate RAF265, an Oral Drug Administered to Subjects With Locally Advanced or Metastatic Melanoma PHASE1/PHASE2COMPLETED
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer PHASE2COMPLETED
A Study to Look at the Electrical Activity of the Heart in Subjects With Solid Tumor Cancers, Before and After Receiving the Study Treatment, GSK1120212 PHASE1COMPLETED
Radiation Therapy and Bortezomib and Cetuximab With or Without Cisplatin to Treat Head and Neck Cancer PHASE1COMPLETED
Phase I Study of Novel Estrogen Receptor(ER) a36 Modifier Icaritin in Advanced Breast Cancer Patients PHASE1UNKNOWN
BEP Study Phase I (Bevacizumab, Everolimus, Panitumumab) PHASE1COMPLETED
Study of LUT017 Gel to Improve Healing of Skin Wounds After Removal of Benign Lesions in Healthy Adults PHASE1NOT_YET_RECRUITING
FAK Inhibitor in Patients With Advanced Solid Tumors PHASE1NOT_YET_RECRUITING
Evaluation of Human Melanocytes After the Use of PRP Versus Fractional CO2 Laser in Vitiligo nanUNKNOWN
Uncovering Genes Behind Cartilage Tumors and Vascular Anomalies Using Genomic Sequencing nanRECRUITING
Biomarkers in Samples From Patients With Endometrial Cancer nanWITHDRAWN
p38 Mitogen-Activated Protein Kinase (MAPK) and Steroid Insensitivity in Asthma nanCOMPLETED
BRAF-/MEK-Inhibition With Dabrafenib and Trametinib in Melanoma Patients nanCOMPLETED
Clinical, Genetic, and Epidemiologic Study of Children and Adults With RASopathies nanRECRUITING
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma nanCOMPLETED
RASopathy Biorepository nanRECRUITING
Targeted Treatment Plus Tislelizumab and HAIC for Advanced CRCLM Failed From Standard Systemic Treatment nanACTIVE_NOT_RECRUITING

Related proteins — ESM-2 sequence neighbours (a MAPK10 binder may also engage these)

ProteinNameSimilarity
P49187 — 1.000 P49187 →
Q61831 — 1.000 Q61831 →
MAPK8 Mitogen-activated protein kinase 8 0.998 landscape →
P49186 — 0.996 P49186 →
MAPK9 Mitogen-activated protein kinase 9 0.993 landscape →
Q9WTU6 — 0.993 Q9WTU6 →
Q8QHK8 — 0.992 Q8QHK8 →
Q90327 — 0.991 Q90327 →
O42099 — 0.990 O42099 →
P49185 — 0.990 P49185 →
P79996 — 0.980 P79996 →
Q91Y86 — 0.980 Q91Y86 →
P62205 — 0.978 P62205 →
Q9WVS4 — 0.975 Q9WVS4 →
MOK MAPK/MAK/MRK overlapping kinase 0.974 landscape →
CHEK1 Serine/threonine-protein kinase Chk1 0.973 landscape →
Q08466 — 0.972 Q08466 →
O35280 — 0.971 O35280 →
O54992 — 0.971 O54992 →
PLK2 Serine/threonine-protein kinase PLK2 0.970 landscape →
Q2TA25 — 0.969 Q2TA25 →
Q28GW8 — 0.969 Q28GW8 →
P70032 — 0.969 P70032 →
Q91ZN7 — 0.969 Q91ZN7 →
Q08467 — 0.969 Q08467 →
Q90ZY4 — 0.969 Q90ZY4 →
Q5R4L1 — 0.968 Q5R4L1 →
Q9R012 — 0.968 Q9R012 →
MAPKAPK5 MAP kinase-activated protein kinase 5 0.968 landscape →
MELK Maternal embryonic leucine zipper kinase 0.968 landscape →